Low allopurinol doses are sufficient to optimize azathioprine therapy in inflammatory bowel disease patients with inadequate thiopurine metabolite concentrations

[1]  J. Macdonald,et al.  Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. , 2013, The Cochrane database of systematic reviews.

[2]  S. Pushpakom,et al.  Natural history of azathioprine-associated lymphopenia in inflammatory bowel disease patients: a prospective observational study , 2011, European journal of gastroenterology & hepatology.

[3]  C. Stedman,et al.  Allopurinol might improve response to azathioprine and 6‐mercaptopurine by correcting an unfavorable metabolite ratio , 2011, Journal of gastroenterology and hepatology.

[4]  Mary C. Henthorn,et al.  A prospective evaluation of the impact of allopurinol in pediatric and adult IBD patients with preferential metabolism of 6-mercaptopurine to 6-methylmercaptopurine. , 2010, Journal of Crohn's & colitis.

[5]  P. Higgins,et al.  Combination of thiopurines and allopurinol: adverse events and clinical benefit in IBD. , 2010, Journal of Crohn's & colitis.

[6]  J. Sanderson,et al.  Low‐dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease , 2010, Alimentary pharmacology & therapeutics.

[7]  M. Schwartz,et al.  Long term efficacy and safety of allopurinol and azathioprine or 6-mercaptopurine in patients with inflammatory bowel disease. , 2009, Journal of Crohn's & colitis.

[8]  J. Mate,et al.  Meta‐analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis , 2009, Alimentary pharmacology & therapeutics.

[9]  W. Bishop,et al.  Initial clinical experience with allopurinol‐thiopurine combination therapy in pediatric inflammatory bowel disease , 2008, Inflammatory bowel diseases.

[10]  J. Sanderson,et al.  Long‐term outcome of using allopurinol co‐therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease , 2008, Alimentary pharmacology & therapeutics.

[11]  A. Ginsberg,et al.  Use of allopurinol with low-dose 6-mercaptopurine in inflammatory bowel disease to achieve optimal active metabolite levels: a review of four cases and the literature. , 2008, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[12]  R. Gearry,et al.  Thiopurine hepatotoxicity in inflammatory bowel disease: the role for adding allopurinol. , 2008, Expert opinion on drug safety.

[13]  S. Hanauer,et al.  Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[14]  J. Lewis,et al.  Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. , 2006, Gastroenterology.

[15]  S. Hanauer,et al.  Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine , 2005, Alimentary pharmacology & therapeutics.

[16]  A. von Eckardstein,et al.  Therapeutic drug monitoring of thiopurine drugs in patients with inflammatory bowel disease or autoimmune hepatitis , 2004, European journal of gastroenterology & hepatology.

[17]  D. Hommes,et al.  Pharmacokinetics of 6-Mercaptopurine in Patients with Inflammatory Bowel Disease: Implications for Therapy , 2004, Therapeutic drug monitoring.

[18]  K. Rentsch,et al.  Thiopurine S-methyltransferase polymorphisms: efficient screening method for patients considering taking thiopurine drugs , 2004, European Journal of Clinical Pharmacology.

[19]  S. Targan,et al.  6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. , 2002, Gastroenterology.

[20]  T. Bayless,et al.  Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease , 2001, Gut.

[21]  S. Targan,et al.  Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. , 2000, Gastroenterology.

[22]  R. Modigliani,et al.  Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. , 2000, The Cochrane database of systematic reviews.

[23]  N. Weyer,et al.  PHARMACOKINETICS AND DISPOSITION , 1998 .

[24]  Y. Théorêt,et al.  6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity. , 1996, Gut.

[25]  W. Sandborn,et al.  An intravenous loading dose of azathioprine decreases the time to response in patients with Crohn's disease. , 1995, Gastroenterology.

[26]  R. Weinshilboum,et al.  Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine. , 1995, British journal of clinical pharmacology.

[27]  H. Simmonds,et al.  Low-dose allopurinol plus azathioprine/ cyclosporin/prednisolone, a novel immunosuppressive regimen , 1993, The Lancet.

[28]  J. Lilleyman,et al.  Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  C. Harrington,et al.  Metabolism of azathioprine to 6-thioguanine nucleotides in patients with pemphigus vulgaris. , 1987, British journal of clinical pharmacology.